ERCC8 and breast carcinoma: Joint effect analysis revealed increased risk of breast cancer with the ERCC8 0/0 and ERCC6 2/4 diplotype combination (OR 5.31, 95% CI 1.22–23.09, p = 0.026) and the ERCC8 0/5 and ERCC6 0/0 diplotype combination (OR 5.09, 95% CI 1.23, 21.03, p = 0.025) compared with the reference category (Table 2B).